Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $75 price target The firm believes the stock’s value will be driven by confidence in daraxonrasib’s second-line metastatic pancreatic ductal adenocarcinoma opportunity given the “highly encouraging” data presented to date. Piper sees share upside ahead of the first-line mPDAC data disclosure in the second half of 2025, which it believes could more than double the addressable patient population for daraxonrasib.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines initiated with an Overweight at Piper Sandler
- Revolution Medicines initiated with an Outperform at LifeSci Capital
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Overweight at Wells Fargo
- Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating